Once secreted, IL-33 interacts with immune cells expressing ST2, initiating downstream signalling cascades in the same cells that can ultimately lead to tumour suppression or promotion, depending on the prevailing immune context and local microenvironment. Here, IL33 is linked to neoplasm.